China's Neo Brain-Computer Interface: Global Implications for the BCI Market

Executive summary

In this episode the Science Friday team discusses China's March approval of a brain computer interface called Neo, developed by Neurocl Technology. Unlike brain-implants that reach into tissue, Neo rests on the dura mater and teams with a soft robotic glove to enable a gripping action for people with limb paralysis due to spinal cord injury. The discussion places Neo in the global BCI landscape, comparing it with Neuralink and Synchron, and situates China’s move within a larger biotech expansion described by Emily Mullen of Wired and Dr Siyun Kang of Georgetown University. The podcast also considers real-world challenges such as device calibration, independence for users, and how regulatory and market dynamics may unfold worldwide.

• Neo sits atop the dura and links to a glove to restore hand function.
• China has designated brain computer interfaces as a strategic service industry and is accelerating approvals.
• US players face slower trials and regulatory timelines, while cross-border deals reflect broader biotech momentum.
• Real-world use will require ongoing calibration and support, raising questions about user independence.

Overview of the podcast

The podcast opens with the news that China approved an invasive brain computer interface named Neo, built by Neurocl Technology, which is placed on the brain’s protective dura rather than penetrating brain tissue. It is designed to work with a soft robotic glove to assist grip for people with paralysis from spinal cord injury. Emily Mullen from Wired compares Neo to other BCIs under development, notably Neuralink’s coin-sized brain implant and Synchron’s vascular approach, outlining the diversity of BCI designs in the field. The discussion then broadens to examine China’s biotech industry, where a Georgetown University scholar, Dr Siyun Kang, explains that China’s growth stems from long-term investments in science, regulation, and an ecosystem shift from manufacturing to innovation. The episode ends with reflections on how these developments may affect global competition, collaboration, and patient access to therapies.

Neo BCI technology and its place in the field

Neo does not require brain tissue penetration. Instead it rests on the dura mater and interfaces with a soft robotic glove, enabling a gripping action for users who have lost hand function. Trials in China involved about three dozen participants, and the technology is now entering the country’s health system with the potential for rapid rollout. By contrast, Neuralink pursues a coin-sized implant with ultra-thin electrode threads extending into brain tissue, while Synchron uses a stent-like device placed in a blood vessel to sit against the brain. These approaches illustrate a spectrum of BCI designs aimed at different neurological targets and patient needs, all under active investigation.

Global landscape and regulatory context

The conversation highlights an emerging global race in BCIs and biotech more broadly. In the United States, clinical trials continue but progress is often slower due to regulatory pathways. Emily Mullen notes the US is watching China to gauge commercial viability and patient usefulness in daily life. China’s government has positioned BCI as a strategic industry and is integrating it into a five-year plan, signaling intent to compete with the US in a high-stakes tech sector. The episode also touches on major licensing activity, such as Bristol Myers Squibb’s $15 billion deal with a Chinese company for early-stage drug candidates, underscoring China’s growing role in global pharma and biotech pipelines.

Industry implications and future outlook

Dr Siyun Kang discusses how China’s biotech ascent is driven by faster, lower-cost early-stage development, a large patient pool for trials, and a regulatory environment that can accelerate timelines. This combination could attract more startups to Chinese ecosystems, potentially shifting the center of gravity in biotechnology. However, questions remain about talent migration, the pricing of drugs and therapies, and how collaboration versus competition will shape global access to new treatments. The podcast also considers whether the rise of Chinese biotech could alter supply chains, manufacturing, and the broader ecosystem supporting medical innovation, including talent, capital, and regulatory harmonization. The discussion concludes by emphasizing careful, coordinated approaches to cross-border innovation that prioritize patient access and scientific advancement without stifling collaboration or provoking policy backlash.

Applications and patient experience

BCIs like Neo are framed as assistive technologies intended to restore independence for individuals with paralysis. A key practical issue is device calibration: most BCIs require weekly set-up by a field engineer, and patients may not be able to power on or calibrate devices themselves. These realities raise important questions about how independent users can become and what support systems must accompany commercialization to ensure real-world utility and safety.